JP2024540303A - Ｐｉ３ｋ－アルファ阻害剤、その調製方法及び使用方法 - Google Patents

Ｐｉ３ｋ－アルファ阻害剤、その調製方法及び使用方法 Download PDF

Info

Publication number
JP2024540303A
JP2024540303A JP2024526614A JP2024526614A JP2024540303A JP 2024540303 A JP2024540303 A JP 2024540303A JP 2024526614 A JP2024526614 A JP 2024526614A JP 2024526614 A JP2024526614 A JP 2024526614A JP 2024540303 A JP2024540303 A JP 2024540303A
Authority
JP
Japan
Prior art keywords
compound
iii
solid
formula
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540303A5 (enExample
Inventor
アンドレ レスカーボー，
アレッサンドロ ボエツィオ，
スレンドラ ピー． シン，
チンリン チェ，
シーイー ジャン，
ホンヤン ヘ，
チウシャン ジョウ，
ジャジャ ジョウ，
ユアン リン，
ウェイ グ，
ミン ル，
ユンフェイ ジョウ，
シージャン ゴン，
ジャフイ チェン，
シャオホン ワン，
チャンボ イン，
Original Assignee
リレー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リレー セラピューティクス， インコーポレイテッド filed Critical リレー セラピューティクス， インコーポレイテッド
Publication of JP2024540303A publication Critical patent/JP2024540303A/ja
Publication of JP2024540303A5 publication Critical patent/JP2024540303A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024526614A 2021-11-03 2022-11-03 Ｐｉ３ｋ－アルファ阻害剤、その調製方法及び使用方法 Pending JP2024540303A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263474P 2021-11-03 2021-11-03
CN2021128533 2021-11-03
US63/263,474 2021-11-03
CNPCT/CN2021/128533 2021-11-03
PCT/US2022/079221 WO2023081757A1 (en) 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2024540303A true JP2024540303A (ja) 2024-10-31
JP2024540303A5 JP2024540303A5 (enExample) 2025-11-06

Family

ID=86242193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526614A Pending JP2024540303A (ja) 2021-11-03 2022-11-03 Ｐｉ３ｋ－アルファ阻害剤、その調製方法及び使用方法

Country Status (13)

Country Link
US (1) US20260125374A1 (enExample)
EP (1) EP4426314A4 (enExample)
JP (1) JP2024540303A (enExample)
KR (1) KR20240112283A (enExample)
CN (1) CN118401245A (enExample)
AU (1) AU2022381187A1 (enExample)
CA (1) CA3236861A1 (enExample)
CL (1) CL2024001364A1 (enExample)
IL (1) IL312466A (enExample)
MX (1) MX2024005429A (enExample)
PE (1) PE20250676A1 (enExample)
TW (1) TW202334136A (enExample)
WO (1) WO2023081757A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297625B2 (en) 2020-04-29 2026-05-01 Relay Therapeutics Inc PI3K-alpha inhibitors and methods of using them
WO2024055992A1 (zh) * 2022-09-14 2024-03-21 南京再明医药有限公司 三环化合物及其应用
WO2024097721A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
MA38884A1 (fr) * 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
JP7426398B2 (ja) * 2019-02-26 2024-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体
IL297625B2 (en) * 2020-04-29 2026-05-01 Relay Therapeutics Inc PI3K-alpha inhibitors and methods of using them

Also Published As

Publication number Publication date
AU2022381187A1 (en) 2024-05-16
EP4426314A1 (en) 2024-09-11
WO2023081757A1 (en) 2023-05-11
CA3236861A1 (en) 2023-05-11
EP4426314A4 (en) 2025-10-01
MX2024005429A (es) 2024-05-21
CN118401245A (zh) 2024-07-26
KR20240112283A (ko) 2024-07-18
TW202334136A (zh) 2023-09-01
US20260125374A1 (en) 2026-05-07
CL2024001364A1 (es) 2024-10-25
IL312466A (en) 2024-06-01
PE20250676A1 (es) 2025-03-04

Similar Documents

Publication Publication Date Title
CN114728918B (zh) Rip1抑制性化合物及其制备和使用方法
WO2023060262A1 (en) Pi3k-alpha inhibitors and methods of use thereof
CA3154862A1 (en) Shp2 phosphatase inhibitors and methods of making and using the same
US20260125374A1 (en) Pi3k-alpha inhibitors and methods of making and using the same
CA3099037A1 (en) Rip1 inhibitory compounds and methods for making and using the same
CN116261562A (zh) PI3K-α抑制剂和其使用方法
CN116615426A (zh) Fgfr抑制剂和其制造和使用方法
TW200806664A (en) Azaindoles useful as inhibitors of janus kinases
CN119486992A (zh) PI3Kα抑制剂及其使用方法
WO2019189732A1 (ja) 光学活性な架橋型環状２級アミン誘導体
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
CN118201896A (zh) PI3K-α抑制剂和其使用方法
EP4426286A1 (en) Bifunctional pi3k-alpha inhibitors and uses thereof
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
TW202527954A (zh) PI3Kα抑制劑及其製造與使用方法
EP4648766A1 (en) Pi3k inhibitors and methods of making and using the same
CN118251217A (zh) PI3Kα抑制剂及其使用方法
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
EA051309B1 (ru) Ингибиторы pi3k-альфа и способы их получения и использования
US20260131009A1 (en) Bifunctional pi3k-alpha inhibitors and uses thereof
HK40074209A (en) Shp2 phosphatase inhibitors and methods of making and using the same
EA045207B1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
NZ743251A (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251028